Japan's Act on the Safety of Regenerative Medicine (再生医療等安全性確保法, enacted 2014) created a three-tier classification system that sorts regenerative medicine providers by the risk level of the cells they work with. Most English-language commentary stops at a single paragraph describing the tiers, which leaves practitioners with a frustratingly incomplete picture of their actual legal obligations. The Type II classification sits in the middle of that ladder, and the middle is always the messiest place to be: too risky for the lightest touch, not risky enough to attract the scrutiny that clarifies everything. What follows is a close reading of the statutory text, the accompanying Cabinet Office ordinances, and the Ministry of Health, Labour and Welfare (MHLW) guidance documents published through early 2025, aimed at anyone who needs to understand what operating as a Type II provider actually looks like in practice.
The three-tier logic and where Type II sits ¶
The Act divides all regenerative medicine procedures into Type I, Type II, and Type III based on a risk matrix that weighs cell origin (autologous vs. allogeneic vs. xenogeneic), degree of manipulation, and the clinical vulnerability of the target population. Type I covers the highest-risk procedures: allogeneic or xenogeneic cells that have been substantially manipulated, or any embryonic/induced pluripotent stem cell (iPSC) application. Type III covers low-risk autologous procedures with minimal manipulation, such as platelet-rich plasma in some configurations. Type II occupies the space between those poles. Concretely, it covers allogeneic cell therapies that carry moderate risk and substantially manipulated autologous cells that do not involve pluripotent stem cells. The practical consequence of landing in Type II is that a provider must submit a plan to a certified Special Committee for Regenerative Medicine (特定認定再生医療等委員会) rather than to a merely certified committee, and must also notify MHLW directly. The committee layer is not cosmetic: the certified special committee has stricter membership requirements, including mandatory external experts in bioethics and patient advocacy.
What the notification process actually requires ¶
A Type II provider must file a Regenerative Medicine Provision Plan (再生医療等提供計画) with a certified Special Committee before beginning any procedure. The plan document itself is prescribed in MHLW Form No. 1 and must include: the name and licence number of the medical institution; a detailed description of the cell processing method, including equipment, culture media, and QC release criteria; a risk-benefit assessment citing any prior clinical data; the informed consent protocol; and an adverse event reporting schedule. Once the Special Committee reviews and approves the plan, the provider submits it to MHLW via the online system (再生医療等提供計画届出システム). MHLW then has 90 days to review Type II submissions — compared with 30 days for Type III and a full approval requirement (not just notification) for Type I. During that 90-day window, the provider may not begin the procedure. If MHLW raises no objection within 90 days, the plan is deemed accepted. This differs from Type I, where silence does not equal acceptance: Type I requires an affirmative MHLW approval.
Cell processing: what Type II permits and what it does not ¶
Under Article 35 of the Act and the related Cabinet Order, Type II providers may perform substantial manipulation of autologous somatic cells, including expansion culture beyond a single passage, genetic modification for non-permanent therapeutic purposes under strict conditions, and combination with scaffold materials classified as medical devices under the Pharmaceutical and Medical Device Act. What Type II explicitly prohibits is any use of embryonic stem cells or iPSCs — those automatically push the procedure into Type I regardless of other factors. It also prohibits xenogeneic cell components in the final product; even trace xenogeneic feeder cell residues in the culture process can reclassify a procedure upward if they are detectable in the final cell preparation. Allogeneic use under Type II is permitted but only for specific cell types listed in MHLW's risk categorisation table, which was last substantively updated in 2020. Mesenchymal stromal cells (MSCs) derived from bone marrow and expanded in a GMP-aligned environment frequently appear in Type II filings, making MSC-based therapies the de facto reference case for understanding where the tier's practical boundary sits.
The Special Committee: membership rules that constrain your choices ¶
A provider cannot simply use any MHLW-certified committee for Type II review. The committee must hold the higher 'certified special' designation, which requires at least six members, including at least one physician with relevant clinical expertise, one person with legal or bioethical expertise, one individual representing the patient or public interest who has no medical licence, and — critically — at least two members external to the medical institution submitting the plan. Committee meetings reviewing Type II plans must also reach quorum with the external members present; a quorum of only internal members is insufficient for Type II even if it would be sufficient for Type III. Providers in rural prefectures have sometimes found this requirement logistically difficult, since certified special committees are concentrated in major urban research hospitals in Tokyo, Osaka, and Nagoya. The practical workaround is to contract with a qualifying committee at a distant institution, which adds time and a per-review fee that varies but typically ranges from several hundred thousand yen to over one million yen depending on the committee and the complexity of the plan.
Adverse event reporting: the timelines that catch people off guard ¶
Article 40 of the Act establishes mandatory adverse event reporting, and the timelines differ by severity in ways that providers routinely underestimate. Serious unexpected adverse reactions — defined as death or life-threatening events not anticipated in the approved plan — must be reported to MHLW within 15 days of the provider becoming aware. Serious expected adverse reactions still require reporting, but within 30 days. Non-serious adverse events must be captured in the annual implementation report filed each year by the end of January covering the previous calendar year. A Type II provider who fails to file the annual report risks administrative guidance, and repeated failure can result in an order to suspend provision of the relevant procedure. The 15-day window for serious unexpected events is the one most likely to cause compliance failures, partly because the clock starts at awareness, not at confirmed diagnosis, meaning a provider cannot delay reporting while awaiting a pathology result if the clinical picture already suggests a serious unexpected reaction.
How Type II differs from Type III in practical terms ¶
The comparison with Type III is where the classification system's stakes become concrete. A Type III provider uses a standard certified committee (not a certified special committee), faces a 30-day notification period rather than 90 days, and is not subject to the same mandatory QC release criteria in the submitted plan. Type III adverse event reporting timelines are also somewhat more relaxed: the 15-day window for serious unexpected events applies, but the definition of 'expected' is interpreted more permissively given the lower inherent risk of the procedures involved. Practitioners who believe their procedure qualifies as Type III but may actually belong in Type II are a recurring concern in MHLW guidance. A substantially manipulated autologous cell preparation — for instance, adipose-derived stromal cells expanded beyond three passages and administered systemically — is likely to be classified as Type II even if the provider intends it as Type III. MHLW has issued informal clarification letters on this boundary, though no formal binding rule list exists in English.
Ongoing obligations once a Type II plan is accepted ¶
Acceptance of a Type II plan is not a one-time event. If a provider modifies the cell processing method, changes the QC release criteria, adds a new patient population, or alters the informed consent document in a substantive way, a plan amendment notification must be filed and must again go through the certified special committee before submission to MHLW. Minor administrative changes — such as updating a contact address or personnel listing — can be filed directly without committee re-review, but the line between 'minor' and 'substantive' is defined by MHLW guidance rather than the statutory text, and the guidance uses language that requires interpretive judgment. Providers should also be aware that the certified special committee itself is subject to periodic MHLW inspection, and if a committee loses its certified special status, all active Type II plans it oversees must be transferred to another qualifying committee within a specified transition period, creating an operational continuity risk that is easy to overlook at plan inception.
Japan's regenerative medicine legislation is more granular than its reputation in English-language summaries suggests, and the Type II tier is where that granularity bites hardest: the 90-day notification clock, the certified special committee membership rules, and the amendment-filing obligations together create a compliance surface that rewards careful advance planning far more than reactive adjustment. Anyone building a Type II programme would do well to read MHLW Form No. 1 in full before choosing a committee, not after.